ProMetic’s Plasminogen Treatment Secures Fast Track Status

ProMetic Life Sciences’ plasminogen drug candidate ProMetic has secured fast track designation for the treatment of congenital plasminogen deficiency.

The treatment, which also secured orphan drug designation from the FDA and European Commission, currently is being evaluated in a phase 2/3 trial.

Plasminogen is a protein synthesized in the liver involved in wound healing, cell migration, tissue reconstruction and other processes.